Treatment of Knee Osteoarthritis with Oral Chondroitin Sulfate

Advances in Pharmacology

Volumn 53, Issue , 2006, Pages 523-539

  Uebelhart, Daniel ^a,b   Knols, Ruud ^a   de Bruin, Eling D ^a,c   Verbruggen, Gust ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c ETH ZURICH   (Switzerland)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; KNEE OSTEOARTHRITIS; METHODOLOGY; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; ARTHRALGIA; CHONDROITIN SULFATES; HUMANS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33846129131     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)53027-8     Document Type: Review

References (33)

1. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., Christy W., Cooke T.D., Greenwald R., and Hochberg M. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum. 29 (1986) 1039-1049
2. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (ACR). Recommendations for the medical management of osteoarthritis of the hip and the knee. Arthritis Rheum. 43 (2000) 1905-1915
3. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15 (1988) 1833-1840
4. Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., and Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage 6A (1998) 25-30
5. Bucsi L., and Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 6A (1998) 31-36
6. Committee for Proprietary Medicinal Products (CPMP). "Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis." (1998), European Agency for the Evaluation of Medicinal Products, London
7. Conrozier T. Anti-arthrosis treatments: Efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med. 27 (1998) 1862-1865
8. Cooper C. Epidemiology of osteoarthritis. In: Klippel J.H., and Dieppe P.A. (Eds). "Rheumatology" (1998), Mosby, London 1-20
9. Cooper C., Snow S., McAlindon T.E., Kellingray S., Stuart B., Coggon D., and Dieppe P.A. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum. 43 (2000) 995-1000
10. Dickersin K., Scherer R., and Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 309 (1994) 1286-1291
11. Huskisson E.C. Assessment for clinical trials. Clin. Rheum. Dis. 2 (1976) 37-49
12. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., et al. EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis. Ann. Rheum. Dis. 62 (2003) 1145-1155
13. Landis J., and Koch G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
14. Leeb B.F., Schweitzer H., Montag K., and Smolen J.S. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J. Rheumatol. 27 (2000) 205-211
15. Lequesne M.G., Mery C., Samson M., and Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Scand. J. Rheumatol. 65 (1987) S85-S89
16. L'Hirondel J.L. Klinische Doppelblindstudie mit oral verabreichtem Chrondointinsulphat gegen Placebo bei der tibiofemoralen Gonarthrose. Litera Rheumatol. 14 (1992) 77-85
17. Malaise M., Marcolongo R., Uebelhart D., and Vignon E. Efficacy and tolerability of 800 mg oral chrondroitin 4&6 sulfate in the treatment of knee osteoarthritis: A randomised, double blind, multicentre study versus placebo. Litera Rheumatol. 24 (1999) 31-42
18. May W.L., and Johnson W.D. Generalized estimating equations for multivariate response with the variates having different distributions. J. Biopharm. Stat. 6 (1996) 139-153
19. Mazieres B., Combe B., Phan Van A., Tondut J., and Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J. Rheumatol. 28 (2001) 173-181
20. Mazzuca S.A., Brandt K.D., Katz B.P., Chambers M., Byrd D., and Hanna M. Effects of self-care education on the health status of inner-city patients with osteoarthritis of the knee. Arthritis Rheum. 40 (1997) 1466-1474
21. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for the treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 283 (2000) 1469-1475
22. Messier S.P., Loeser R.F., Mitchell M.N., Valle G., Morgan T.P., Rejeski W.J., and Ettinger W.H. Exercise and weight loss in obese older adults with knee osteoarthritis: A preliminary study. J. Am. Geriatr. Soc. 48 (2000) 1062-1072
23. Michel B.A., Stucki G., Frey D., De Vathaire F., Vignon E., Bruehlmann P., and Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: A randomized controlled trial. Arthritis Rheum. 52 (2005) 779-786
24. Murray C.J.L., and Lopez A.D. "The Global Burden of Disease" (1997), World Health Organisation, Geneva
25. Pavelka K., Manopulo R., and Bucsi L. Double-blind, dose-effect study of oral chondroitin 4&6 sulfate 1200 mg, 800 mg, 200 mg and placebo in the treatment of knee osteoarthritis. Litera Rheumatol. 24 (1999) 21-30
26. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., and Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: A comprehensive meta-analysis. Arch. Int. Med. 163 (2003) 1514-1522
27. Spector T.D., Cicuttini F., Baker J., Loughlin J., and Hart D. Genetic influences in women: A twin study. BMJ 312 (1996) 940-943
28. Uebelhart, D., Knüsel, O., Osterkorn, K., Berz, S., Przybylski, C., and Theiler, R. Oral chondroitin sulfate in patients with femorotibeal osteoarthritis: A six-month multicentre, randomised double-blind, placebo-controlled, parallel-group study. Unpublished (personal communication).
29. Uebelhart D., Thonar E.J., Delmas P.D., Chantraine A., and Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cartilage 6A (1998) 39-46
30. Uebelhart D., Malaise M., Marcolongo R., De Vathaire F., Piperno M., Mailleux E., Fioravanti A., Matoso L., and Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 12 (2004) 269-276
31. Verhagen A., de Vet H., de Bie R., Kessels A.G., Boers M., Bouter L.M., and Knipschild P.G. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J. Clin. Epidemiol. 51 (1998) 1235-1241
32. Zeger S., and Liang L. Longitudinal data analysis using generalized linear models. Biometrics 73 (1986) 13-22
33. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., Hauselmann H.J., Herrero-Beaumont G., Jordan K., Kaklamanis P., Leeb B., Lequesne M., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 64 (2005) 669-681